FBRX
Forte Biosciences Inc
NASDAQ · Biotechnology
$27.59
-1.22 (-4.23%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 45.34M | 44.14M | 46.50M |
| Net Income | -10,345,422 | -12,888,213 | -11,210,008 |
| EPS | — | — | — |
| Profit Margin | -22.8% | -29.2% | -24.1% |
| Rev Growth | -2.5% | -3.2% | -9.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 66.90M | 74.91M | 81.84M |
| Total Equity | 245.10M | 274.64M | 271.93M |
| D/E Ratio | 0.27 | 0.27 | 0.30 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -16,926,895 | -17,594,581 | -16,493,957 |
| Free Cash Flow | -9,838,618 | -11,802,396 | -11,084,789 |